Our study provides a deeper understanding of the ferroptosis‐related mechanisms driving sorafenib resistance in HCC and suggests that the inhibition of the COPS5–MK2–HSPB1 axis is a potential therapeutic strategy for overcoming sorafenib resistance in HCC. This evidence concerns the gene MAPKAPK2 and hepatocellular carcinoma.